Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7783082 | 0.81 | CA12 (0.55) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL3297438 | 0.81 | CNR1 (0.53) | SMN1; SMN2MAPTGAA | |
| SCHEMBL3300429 | 0.80 | TACR1 (0.52) | CA12CA2CA9MAPT | |
| SCHEMBL6815481 | 0.80 | GAA (0.55) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL5899116 | 0.80 | CA1 (0.61) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL3305183 | 0.78 | CNR1 (0.49) | SMN1; SMN2ALDH1A1KMT2AGAAHTT | |
| SCHEMBL2474840 | 0.75 | KMT2A (0.74) | CA12CA1CA2CA9PTGER1 | |
| SCHEMBL9781763 | 0.75 | CA12 (0.66) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL1968355 | 0.75 | CA12 (0.66) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL3302245 | 0.74 | MAPT (0.66) | CA12CA1CA2CA9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093864-A1 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2010-04-15 | — | — | US | claimed |
| EP-2074085-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | Lica Pharmaceuticals A/S (DK) | 2009-07-01 | — | — | EP | claimed |
| WO-2008043840-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2008-04-17 | — | — | WO | claimed |
| US-20100093864-A1 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2010-04-15 | — | — | US | disclosed |
| EP-2074085-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | Lica Pharmaceuticals A/S (DK) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008043840-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093864-A1 | ANTI-INFECTIVE THIOUREA COMPOUNDS | TST, TPX2, TPMT | CA12 2532/4885CA1 4365/4885CA2 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.